GSK-104020



Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life
Combined Measles, Mumps, Rubella, Varicella Vaccine
104020
NCT00126997
Measles; Mumps; Rubella; Varicella
Phase 4
 
An annotated case report form is not available for this study. A blank case report form will be provided.
October 2014